# Epitalon Rating: Early — Mostly animal or cell studies; few or uncontrolled human data Type: Compound Updated: 2026-08-06 Canonical: https://heretic.bio/articles/epitalon-aedg-tetrapeptide-telomerase-pineal-axis-and-geroprotective-evidence.html > Epitalon (AEDG) is a synthetic tetrapeptide modeled on the bovine pineal extract epithalamin, developed by Khavinson's St. Petersburg group. It activates telomerase and extends telomeres ~33% in human cell lines, with 2025 work adding a second route via ALT; animal lifespan data is positive. Human data is limited to two small, single-site Russian trials, retinitis pigmentosa (n=162) and circadian measures (n=75), with no Western replication. > **Aliases:** Epithalon, Epithalone, Epithalamin (parent extract) **Sequence:** Ala-Glu-Asp-Gly (AEDG) — tetrapeptide **Molecular Weight:** ~390 Da (free base); salts commonly acetate or trifluoroacetate (TFA) **Origin:** Synthetic tetrapeptide based on amino acid composition of Epithalamin (bovine pineal gland extract). AEDG was confirmed in **authentic pineal polypeptide complex solution in 2017** (Khavinson et al., PMID [29124531](https://pubmed.ncbi.nlm.nih.gov/29124531/)) — it is endogenous, not purely a drug invention. * * * ## Overview Epitalon is a tetrapeptide (Ala-Glu-Asp-Gly) synthesized by **Vladimir Khavinson** and his team at the St. Petersburg Institute of Bioregulation and Gerontology based on the amino acid composition of **Epithalamin** , a polypeptide extract from the bovine pineal gland. It is one of the most studied anti-aging peptides, with research spanning over **25 years** since its 2001 Russian patent (referenced in [PMC11943447](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11943447/)). It occupies the unique position of being a Russian Federation peptide bioregulator (short regulatory peptide class). Epitalon's most celebrated property is its ability to **activate telomerase** and **elongate telomeres** — the protective caps on chromosomes that shorten with each cell division. This positions it as a potential **geroprotector** at the most fundamental cellular level. **Evidence Level (as of Sept 2026):** Moderate-to-strong preclinical; modest human evidence. Key 2025 mechanistic advance: **dual mechanism** confirmed — telomerase upregulation AND Alternative Lengthening of Telomeres (ALT) activation (Igarashi et al., _Biogerontology_ 2025, **PMID[40908429](https://pubmed.ncbi.nlm.nih.gov/40908429/) / [PMC12411320](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12411320/)**). Telomerase activity alone is now known to be insufficient in many human cell lines; ALT adds a parallel telomere-maintenance route. * * * ## Mechanism of Action ### Telomerase Activation & ALT (Updated 2025) * **Reactivates hTERT expression** in telomerase-negative human fetal fibroblast cultures (Khavinson, Bondarev, Butyugov, 2003, PMID [12937682](https://pubmed.ncbi.nlm.nih.gov/12937682/)) * **Elongates telomeres** by an average of **33.3%** in human somatic cells * **2025 update — ALT pathway also engaged:** Igarashi S et al., _Biogerontology_ 2025 Sep 4;26(5):178 (**[PMC12411320](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12411320/)**). Demonstrated Epitalon increases telomere length in human cell lines through **either** telomerase upregulation **or** Alternative Lengthening of Telomeres (ALT) activity, depending on baseline hTERT status. This is a mechanism-resolving finding: it explains how Epitalon can act on ALT-positive tumors as well as telomerase-reactivated somatic cells (and supports its reported anti-tumor profile). * Control fibroblasts lost mitotic capacity after passage 34; Epitalon-treated cells continued past passage 44 (Khavinson, May 2004 _Bull Exp Biol Med_). * Telomere repeat amplification protocol (TRAP) confirms telomerase induction in HeLa and 602/17 fetal fibroblasts. ### Pineal Gland & Melatonin Axis * **Restores melatonin synthesis** in aged pinealocytes by elevating AANAT and pCREB expression (more potent at 3h than Vilon; PMID [22816096](https://pubmed.ncbi.nlm.nih.gov/22816096/), Khavinson 2012) * **In vivo in old rhesus monkeys (22.8 ± 1 yr):** IM Epitalon normalized cortisol and stimulated melatonin synthesis in age-dependent manner (Goncharova et al.) * **In vitro conflict:** Djeridane et al. 2003 (PMID [12809170](https://pubmed.ncbi.nlm.nih.gov/12809170/)) found **no** direct melatonin secretion effect in isolated perifused pineal glands from young/old rats — suggesting Epitalon acts on synthesis machinery rather than secretion per se * **Human circadian RCT signal:** 75 women, 0.5 mg/day sublingual × 20 days → 1.6× urinary 6-sulfatoxymelatonin (aMT6s) vs placebo; Clock gene expression −1.8×, Cry2 +2×, Csnk1e −2.1× (p < 0.05). Mechanistic support for geroprotective activity via clock gene modulation. ### Gene Regulation & DNA Binding * **Direct DNA binding** confirmed (FITC-labeled Epitalon penetrates HeLa cells and reaches the nucleus; binds CAG-repeat sequences susceptible to cytosine methylation) * In silico: binds ATTTG and ATTTC promoter sequences — the **ATTTC motif is repeated multiple times in the telomerase gene promoter** (Khavinson 2004) * **Epigenetic regulation:** interacts with histone H1/3 and H1/6 (binding energies −56.49 and −64.51 kcal/mol; molecular dynamics AMBER12EHT) — first non-DNA epigenetic route * **Plant system validation:** _Nicotiana tabacum_ callus assays confirm Epitalon binds CAG regions of plant DNA * Solovyev et al.: Epitalon reduces dsDNA melting temperature by up to **41 °C** at 0.1 M NaCl ionic strength ### Transporter Binding (New 2020 finding) * **In silico docking:** strong binding to LAT1, LAT2, PEPT1, PEPT2 amino acid transporters (comparable to known PEPT1 inhibitors). Suggests **anti-cancer mechanism via amino acid transport blockade** — explains observed tumor-suppression without direct cytotoxicity. ### Antioxidant & Nrf2 * **Direct Keap1/Nrf2 promoter binding** demonstrated (Gutop et al.) — upregulates SOD-1, NQO1, catalase expression * In _D. melanogaster_ , 16,000-fold lower concentration than melatonin achieves comparable lifespan extension — "signaling role" rather than stoichiometric antioxidant ### Other Mechanisms * **STAT1 phosphorylation** in THP-1 monocytic leukemia cells (receptor-independent; additive with LPS → ERK1/2 phosphorylation; **suppresses STAT3**) * **Cholinergic:** +10–25% AChE/BuChE activity in SH-SY5Y (Nalieva et al.); −20% soluble APP secretion → potential AD-relevant modulation * **Anti-mutagenic** in albino & grey mice (sperm head abnormalities, micronuclei in peripheral blood erythrocytes) * **Anti-apoptotic:** 2.12-fold reduction in splenic lymphocyte apoptosis post-γ-irradiation (Kozina) * **Cytokine modulation:** IL-2 mRNA elevation in splenocytes (5h vs 20h for Vilon); regioselective hypothalamic IL-2 mRNA changes after IM/intranasal ### Anti-Tumor Effects * **HER-2/neu transgenic FVB/N mice:** 3.7-fold lower HER-2/neu mRNA expression; reduced mammary adenocarcinoma count (p < 0.05) * **C3H/He mice:** 6.5-month study — reduced tumor incidence, multiplicity, localization vs saline * **SAMP-1 mice (accelerated aging model):** Epitalon reduced chromosomal abnormalities more than melatonin in SHR controls * **1,2-dimethylhydrazine colon carcinogenesis model:** significant decrease in cancer incidence * **Frailty-model dependent:** Semenchenko et al. showed Epitalon **either** reduced max lifespan (debilitation/frailty accumulation) **or** enhanced survival (robustness/heterogeneity) depending on dose schedule — non-monotonic dose-response * * * ## Evidence by Biological System ( PMC11943447 taxonomy) Model | Key Findings ---|--- **Human cell lines** | Telomere elongation (33.3%); Hayflick limit overcome; AChE/BuChE modulation; oocyte protection (DNA damage ↓, apoptosis ↓); 2025 bovine oocyte telomerase + JC-1 mito health improvement (Ullah _Life Sci_ 2025) **_D. melanogaster_** | ↑ Lifespan by up to 16% in both sexes (mature/old flies affected); antioxidant at 0.00001% w/w; better antioxidant than Epithalamin at 1000× lower dose **Mice (CBA, C3H/He, FVB/N, SAMP-1, SHR)** | ↑ Lifespan (23-month mice reached 4× control rate; oldest Epitalon mouse 34 mo vs 24 mo control); ↓ chromosomal aberrations 17.1% (SHR); ↑ survival last 10% by 13.3% (SHR); anti-tumor across strains **Rats (Wistar, LIO, Campbell)** | Pinealectomy gastric cell recovery (42 days); Campbell rats retinal functional activity +43.9% (parabulbar) and 2-fold (maternal IP); oral glucose transport ↑2.2–8× in proximal/medial small intestine; nephroprotective in glycerol/cisplatin AKI **Rhesus monkeys** | Old monkeys: melatonin ↑, cortisol normalized; glucose response area ↓ in old (479.6 → 388.9 mM/min); ↑ in young (294.9 → 343.3) **Rabbits (Chinchilla)** | Dansyl-labeled Epitalon integrates rapidly into maternal + fetal tissues under placental insufficiency **Clinical — Retinitis pigmentosa** | n=162 patients, parabulbar 5 µg/eye × 10 days; visual acuity ↑ 0.15–0.20; visual field borders extended in 64.8% by 90–120°; no side effects **Clinical — Circadian** | 75 women, 0.5 mg/day sublingual × 20 days; 1.6× aMT6s vs placebo **Plant (_N. tabacum_)** | Callus proliferation ↑ at low doses (10⁻⁷ M); gene expression changes in CLE/GRF/KNOX families * * * ## 2025 Mechanism Update: Dual Telomere Maintenance The single most significant mechanistic advance for Epitalon in 2025 was the demonstration that **Epitalon engages both the telomerase AND ALT pathways** depending on the baseline hTERT status of the cell (Igarashi S et al., _Biogerontology_ 2025 Sep 4;26(5):178, **PMID[40908429](https://pubmed.ncbi.nlm.nih.gov/40908429/) / [PMC12411320](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12411320/)**). This: 1. Resolves the long-standing puzzle of how a single tetrapeptide produces effects in ALT-positive (telomerase-negative) tumor cells as well as in telomerase-reactivated somatic cells. 2. Confirms Epitalon has activity independent of canonical hTERT induction — broader applicability than previously assumed. 3. Aligns with the documented anti-tumor profile (anti-cancer effect via amino acid transporter blockade is mechanistically independent of telomere status). Companion 2025 finding (Ullah S et al., _Life Sci_ 2025;362:123381, cited in Araj review): Epitalon **enhanced bovine oocyte maturation and post-thawed embryo development** via telomerase + mitochondrial pathways (PGC-1α, Sirt-1, tFAM, BCL2 ↑; JC-1 mito health ↑; intracellular ROS ↓). First evidence that Epitalon accelerates blastocyst expansion/hatching — relevant to reproductive longevity research. * * * ## Doses in studies > ⚠️ **Disclaimer:** Research protocols. Epitalon is not FDA-approved. Quality concerns: **Vanhee et al.** confirmed LC-MS/MS is the only reliable way to distinguish genuine AEDG from EADG (Glu-Ala-Asp-Gly) counterfeit, which arises via N-terminal glutamic acid pyroglutamate formation during heat treatment. Counterfeit risk is non-trivial in unregulated gray market. ### Approaches Reported in the Literature * **Often combined with** Thymogen (Glu-Trut dipeptide) for immune support or [other pineal peptides](peptide-bioregulation-khavinson.html) * **Retinal protocol** (per Russian clinical trial, St. Petersburg IBG): 5 µg/eye parabulbar × 10 days * * * ## Safety Profile Aspect | Assessment ---|--- **Overall safety** | Excellent — no reported toxic, allergic, or adverse effects across 40+ years of Russian clinical use **Acute toxicity** | None observed even at high doses in animal studies **Long-term safety** | Used clinically in Russia since the 1990s **Cancer risk** | **Anti-tumor** rather than pro-tumor — reduces tumor incidence in animal models across multiple strains **FDA status** | Not approved in the United States; **no IND/CTA in US** ; subject of 2026 PCAC compounding panel review (see [FDA Peptide Reclassification 2026 — Regulatory Intelligence](fda-peptide-reclassification-2026.html)) **Russian clinical experience** | n=162 retinitis pigmentosa patients; no side effects reported **Stability concern** | Short peptide; rapid in vivo degradation. Authors of [PMC11943447](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11943447/) recommend acetylation/amidation modification as future direction — **not yet evaluated** **Stereoisomer question** | 8 possible stereoisomers; only L-amino acid form characterized. Other 7 unstudied **Counterfeit risk** | Significant in gray market (EADG vs AEDG confusion, pyroglutamate formation); Vanhee LC-MS/MS is the gold standard * * * ## Clinical Reality Check (Sept 2026) * **No FDA-approved indication anywhere outside Russia** * **Clinical trial landscape:** All published human data is Russian (St. Petersburg IBG, Goncharova lab). Two human signals: retinitis pigmentosa (n=162, parabulbar) and circadian (n=75 women, sublingual). Both small, single-site, no Western replication. * **Mechanism is now better understood** thanks to 2025 Igarashi ALT paper + transporter docking * **Quality control is the active risk:** LC-MS/MS confirmation per Vanhee et al.; the EADG counterfeit is indistinguishable by mass alone * **Stability is an unresolved pharmacokinetic challenge** — no published acetylated/amidated analog studies * * * ## Source & Origin * **Developer:** Vladimir Khavinson (St. Petersburg Institute of Bioregulation and Gerontology) * **Parent compound:** Epithalamin — polypeptide extract from bovine pineal gland (used in Russian clinical practice since 1990s) * **Synthesis:** Short peptide (tetrapeptide) from amino acids based on Epithalamin's active sequence; patented 2001 in Russian Federation * **Endogenous confirmation:** AEDG identified in physiological pineal polypeptide solution in 2017 (Khavinson, Kopylov et al., PMID [29124531](https://pubmed.ncbi.nlm.nih.gov/29124531/)) * **Part of:** Khavinson's systematic approach to peptide bioregulation — see [Khavinson Peptides (Russian Bioregulators)](peptide-bioregulation-khavinson.html) * * * ## Sources 1. Khavinson VKh, Kopylov AT, Vaskovsky BV, Ryzhak GA, Lin'kova NS. (2017). Identification of Peptide AEDG in the Polypeptide Complex of the Pineal Gland. Bull Exp Biol Med 164:41–43. PMID 29124531 — endogenous confirmation (PubMed 29124531) 2. Araj SK, Brzezik J, Mądra-Gackowska K, Szeleszczuk Ł. (2025). Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising Properties. Int J Mol Sci 26(6):2691. PMCID PMC11943447 / PMID 40141333 — comprehensive 25-year synthesis review (PMC11943447, PubMed 40141333) 3. Igarashi S et al. (2025). Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology 26(5):178. PMID 40908429 / PMC12411320 — ALT mechanism resolution (PubMed 40908429, PMC12411320) 4. Khavinson VKh, Bondarev IE, Butyugov AA. (2003). Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med 135:590–2. PMID 12937682 — foundational human cell line result (PubMed 12937682) 5. PubMed 22816096 (PubMed 22816096) 6. Djeridane Y, Khavinson VK, Anisimov VN, Touitou Y. (2003). Effect of a synthetic pineal tetrapeptide (Ala-Glu-Asp-Gly) on melatonin secretion by the pineal gland of young and old rats. J Endocrinol Investig 26:211–215. PMID 12809170 — null in vitro secretion result (PubMed 12809170) 7. Ullah S et al. (2025). Epitalon-activated telomerase enhances bovine oocyte maturation rate and post-thawed embryo development. Life Sci 362:123381. doi 10.1016/j.lfs.2025.123381 — reproductive longevity evidence (DOI 10.1016/j.lfs.2025.123381) 8. Khavinson VKh, Razumovsky MI, Trofimova SV, Grigorian R, Razumovskaya A. (2002). Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuroendocrinol Lett 23:365–368. PMID 12195242 — n=162 retinitis pigmentosa clinical trial (PubMed 12195242) 9. Khavinson VKh et al. (2002). Peptides of pineal gland and thymus prolong human life. Neuroendocrinol Lett 24:233–240. PMID 14523363 (PubMed 14523363) 10. Anisimov VN, Khavinson VK, Morozov VG. (1994). Twenty years of study on effects of pineal peptide preparation: Epithalamin in experimental gerontology and oncology. Ann N Y Acad Sci 31:483–493. PMID 8010617 (PubMed 8010617) 11. Khavinson VKh, Kuznik BI, Ryzhak GA. (2013). Peptide bioregulators: The new class of geroprotectors. Message 2. Clinical studies results. Adv Gerontol 26:20–37. PMID 24003726 (PubMed 24003726)